TY - JOUR
T1 - Antibiotic resistance-the need for global solutions
AU - Laxminarayan, Ramanan
AU - Duse, Adriano
AU - Wattal, Chand
AU - Zaidi, Anita K.M.
AU - Wertheim, Heiman F.L.
AU - Sumpradit, Nithima
AU - Vlieghe, Erika
AU - Hara, Gabriel Levy
AU - Gould, Ian M.
AU - Goossens, Herman
AU - Greko, Christina
AU - So, Anthony D.
AU - Bigdeli, Maryam
AU - Tomson, Göran
AU - Woodhouse, Will
AU - Ombaka, Eva
AU - Peralta, Arturo Quizhpe
AU - Qamar, Farah Naz
AU - Mir, Fatima
AU - Kariuki, Sam
AU - Bhutta, Zulfiqar A.
AU - Coates, Anthony
AU - Bergstrom, Richard
AU - Wright, Gerard D.
AU - Brown, Eric D.
AU - Cars, Otto
N1 - Funding Information:
The Innovative Medicines Initiative , funded by the European Federation of Pharmaceutical Industries and Associations, is the biggest public–private initiative in Europe. It is distinct from the EU Framework Programmes and aims to accelerate the development of better medicines for patients. The initiative seeks to improve collaboration between industry and academia, which has been identified as a potential way forward for some years. 334 40 projects are in motion that cover many areas of medicine including antibiotic resistance (eg, COMBACTE and PreDICT-TB). Further Innovative Medicines Initiative funds will be targeted at antibiotic drug discovery in the New Drugs for Bad Bugs programme, if these funds were to be available at early stages of antibiotic discovery that could have a substantial effect.
Funding Information:
Preclinical development would be done by SMEs, and would aim to mature the drug to be phase 1 ready. A central facility would need to be set up to provide advice to academics and SMEs about preclinical development. Funding could derive from government loans or grants. Phase 1/2 and phase 2 clinical trials would be done by SMEs funded by loans and grants. The central facility would provide advice about clinical development.
PY - 2013/12
Y1 - 2013/12
N2 - The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences affect everybody in the world. Similarities with climate change are evident. Many efforts have been made to describe the many different facets of antibiotic resistance and the interventions needed to meet the challenge. However, coordinated action is largely absent, especially at the political level, both nationally and internationally. Antibiotics paved the way for unprecedented medical and societal developments, and are today indispensible in all health systems. Achievements in modern medicine, such as major surgery, organ transplantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, would not be possible without access to effective treatment for bacterial infections. Within just a few years, we might be faced with dire setbacks, medically, socially, and economically, unless real and unprecedented global coordinated actions are immediately taken. Here, we describe the global situation of antibiotic resistance, its major causes and consequences, and identify key areas in which action is urgently needed.
AB - The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences affect everybody in the world. Similarities with climate change are evident. Many efforts have been made to describe the many different facets of antibiotic resistance and the interventions needed to meet the challenge. However, coordinated action is largely absent, especially at the political level, both nationally and internationally. Antibiotics paved the way for unprecedented medical and societal developments, and are today indispensible in all health systems. Achievements in modern medicine, such as major surgery, organ transplantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, would not be possible without access to effective treatment for bacterial infections. Within just a few years, we might be faced with dire setbacks, medically, socially, and economically, unless real and unprecedented global coordinated actions are immediately taken. Here, we describe the global situation of antibiotic resistance, its major causes and consequences, and identify key areas in which action is urgently needed.
UR - http://www.scopus.com/inward/record.url?scp=84887627398&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(13)70318-9
DO - 10.1016/S1473-3099(13)70318-9
M3 - Review article
C2 - 24252483
AN - SCOPUS:84887627398
SN - 1473-3099
VL - 13
SP - 1057
EP - 1098
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 12
ER -
